Cue Biopharma Inc Revenu Y/Y
Quel est le Revenu Y/Y de Cue Biopharma Inc?
Le Revenu Y/Y de Cue Biopharma Inc est 363.92%
Quelle est la définition de Revenu Y/Y?
La croissance annuelle des revenus des trois dernières années correspond à la croissance moyenne des revenus d’une année sur l’autre au cours des trois dernières années.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Revenu Y/Y des entreprises dans Health Care secteur sur NASDAQ par rapport à Cue Biopharma Inc
Que fait Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Entreprises avec revenu y/y similaire à Cue Biopharma Inc
- Cabot Oil & Gas a Revenu Y/Y de 350.50%
- N.B.I. Industrial Finance a Revenu Y/Y de 350.57%
- Delcath Systems a Revenu Y/Y de 350.63%
- 4 Basebio Ag Na O.N a Revenu Y/Y de 354.33%
- Kinepolis NV a Revenu Y/Y de 355.39%
- Ishares S&P Global s S a Revenu Y/Y de 361.11%
- Cue Biopharma Inc a Revenu Y/Y de 363.92%
- Clearside Biomedical Inc a Revenu Y/Y de 365.02%
- Herald Investment Trust Plc a Revenu Y/Y de 367.65%
- Enviro Technologie a Revenu Y/Y de 370.96%
- TUI AG a Revenu Y/Y de 373.07%
- Tui Ag a Revenu Y/Y de 373.07%
- WELL Health Technologies a Revenu Y/Y de 375.34%